United Therapeutics Corporation (NASDAQ:UTHR) Q1 2022 Results Conference Call May 4, 2022 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson, CEO Michael Benkowitz - President, COO Leigh Peterson - SVP, Product Development Patrick Poisson - EVP, Technical Operations Conference Call Participants Andreas Argyrides - Wedbush Securities Eun Yang – Jefferies Jessica Fye – JPMorgan Joseph Thome - Cowen & Company Operator Good morning, and welcome to the United Therapeutics C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-19847 ...

United Therapeutics Corporation (NASDAQ:UTHR) Q4 2021 Earnings Conference Call February 24, 2022 9:00 AM ET Company Participants Dewey Steadman - Head of IR Martine Rothblatt - Founder, Chairman and CEO Michael Benkowitz - President and COO Conference Call Participants Joseph Thome - Cowen and Company Eun Yang - Jefferies LLC Jessica Fye - JPMorgan Andreas Argyrides - Wedbush Securities Inc. Operator Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter and Full Year 2021 Earnings ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 Registrant's Telephone Number, Including Area Code Securities registered pursuant to Section 12(b) of the Act: Title of each cl ...

United Therapeutics Corporation (NASDAQ:UTHR) Q3 2021 Earnings Conference Call November 3, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO Leigh Peterson - SVP, Product Development James Edgemond - CFO and Treasurer Conference Call Participants Joseph Thome - Cowen and Company Jessica Fye - JPMorgan Hartaj Singh - Oppenheimer Eun Yang - Jefferies Operator Good morning and welcome to the United Therapeutics Corporati ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1984749 (State or Other Jurisdiction of (I.R.S. Employ ...

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2021 Earnings Conference Call August 4, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Leigh Peterson - Senior Vice President, Product Development Conference Call Participants Jessica Fye - JPMorgan Hartaj Singh - Oppenheimer & Company Joseph Thome - Cowen & ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the transition period from to Commission file number 0-26301 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Title of each class Trading Symbol(s) Name of exchange on which registered Common Stock, par value $0.01 ...

Financial Data and Key Metrics Changes - The company aims to increase the number of patients treated from over 8,000 to over 25,000 by 2025, a goal referred to as "25/25" [8][25] - The company expects to achieve approximately half of the required growth from WHO Group 1 pulmonary arterial hypertension and the other half from WHO Group 3 pulmonary hypertension [10][15] Business Line Data and Key Metrics Changes - The company anticipates gaining about 3,000 new patients each from Remodulin, Tyvaso, and Orenitram in the WHO Group 1 category [11][12][13] - The company is the only drug approved for the IPF market segment of patients with pulmonary hypertension, targeting to capture at least 9,000 patients from this group by 2025 [17] Market Data and Key Metrics Changes - There are approximately 50,000 patients being treated for pulmonary hypertension in the U.S., with about 45,000 treated with non-United Therapeutics drugs, indicating a significant market opportunity [14] - The company is focusing on educating new treaters and engaging patients to increase treatment uptake for Tyvaso in the ILD-PH segment [36] Company Strategy and Development Direction - The company is focused on expanding its patient base significantly by leveraging new product approvals and enhancing treatment options [25] - The company has several late-phase clinical trials underway, including studies for Tyvaso in COPD-associated pulmonary hypertension and ralinepag in Group 1 pulmonary hypertension [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the pulmonary hypertension market, citing a meaningful unmet need and the company's capabilities to address it [25][62] - The management believes that the goal of treating 25,000 patients by 2025 is realistic given the annual progression rates of existing patients [62] Other Important Information - The company is developing a once-daily formulation of Orenitram and less painful forms of Remodulin, expected to launch by 2025 [24] - The company is actively building relationships with new treaters and educating them about the benefits of Tyvaso [35] Q&A Session Summary Question: Strategy for Group 3 PH-ILD and patient targeting - Management indicated that they are building relationships with ILD treaters and have ongoing patient engagement efforts to educate patients about Tyvaso [30][36] Question: Commercialization plans for Tyvaso solution vs. Tyvaso DPI - Management stated that they expect a significant number of patients to transition to the dry powder inhaler, estimating a 70-30 split between dry powder and nebulizer usage [41] Question: Growth trajectory of Orenitram post-FREEDOM-EV study - Management noted that they are seeing an uptick in referrals and starts for Orenitram, with ongoing efforts to educate physicians on its value proposition [46][50] Question: TETON program and potential for DPI studies - Management confirmed that once approvals are received for Tyvaso, additional indications for DPI will follow, and they are studying patient preferences for delivery methods [57]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-19847 ...